Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 941 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Five-Year Outcomes with CAR T Cell Therapy February 22, 2021 Picking out the patterns: How scientists are finding cancer’s signatures in... June 15, 2022 Snack Ideas and Tips for Better Sleep November 20, 2020 ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ February 10, 2019 Load more HOT NEWS Evaluation of Primary and Secondary Prevention of Oral Cancer EMA Recommends Granting a Marketing Authorisation for Fruquintinib FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows
